Michael B. Atkins

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Georgina V. Long, Victoria Atkinson, Jonathan Cebon et al. · The Lancet Oncology · 2017 · 246 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

A. B. Ackerman, Oliver Klein, David F. McDermott et al. · Cancer · 2014 · 225 citations

Medicine, Oncology, Pharmacotherapy +17

Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma

Keith T. Flaherty, Sandra J. Lee, Fengmin Zhao et al. · Journal of Clinical Oncology · 2012 · 220 citations · Full text

Medicine, Oncology, Pharmacology +15

The state of melanoma: challenges and opportunities

Glenn Merlino, Meenhard Herlyn, David E. Fisher et al. · Pigment Cell & Melanoma Research · 2016 · 130 citations · Full text

Medicine, Dermatology, Oncology +17

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

Ravi K. Amaravadi, Lynn M. Schuchter, David F. McDermott et al. · Clinical Cancer Research · 2009 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17